Professor Peter Atadja (Dean of School)
Elucidation of the molecular basis of disease, identification and validation of intervention points and therapeutic targets, Disease modelling, Discovery and Development of therapeutic molecules (Small molecular weight and Biologic) – Hit to lead discovery, lead optimization, preclinical and clinical drug development. Among Pioneers of research elucidating epigenetic mechanisms of disease for therapeutic intervention. Discovered HDAC 11, shown to be involved in tumor immunology and other disease mechanisms (see pubmed). Authored or Co-authored ~120 peer-reviewed articles, reviews and book chapters and hundreds of scientific conference plenary presentations, posters and abstracts. Built and led multi-disciplinary international research programmes and teams.
Led the discovery of a number of preclinical drug candidates, 3 clinical development stage drugs and one globally approved and marketed cancer drug (Farydak in relapsed/refractory multiple myeloma). Current interests include bringing genetic and epigenetic understanding into cancers and cancer-types predominant in Africa, identification of unique intervention points and targets for therapy, developing models for drug discovery and biomarkers for therapeutic stratification.
B. Pharm. (Hons), (KNUST, Ghana), M.Sc.,(Hebrew University, Israel)
Ph.D. (University of Calgary, Canada)